What's new? Log in Free sign up

Theratechnologies (THTX)

Company Profile

Company profile

Ticker

THTX, TH

Exchange

Website

www.theratech.com

CEO

Ms. Joanne Choi

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

iBioPharma, Inc., InB:Biotechnologies, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

THTX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Annual report (foreign)

Theratechnologies Reports Financial Results

Material Change Report

Current report (foreign)

Theratechnologies to Announce Fourth Quarter and Full Year 2024

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Material Change Report

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Nantahala Capital Management, LLC

Nantahala Capital Management, LLC

Soleus Capital Master Fund, L.P.

Investissement Quebec

Soleus Capital Master Fund, L.P.

Financial summary

Financial statements Chart THTX financial data

Quarter (USD)	Nov 24	Nov 23	Nov 22	Nov 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Nov 24	Nov 23	Nov 22	Nov 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

THTX institutional ownership history Ownership history

60.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	31	36	-13.9%
Opened positions	4	3	+33.3%
Closed positions	9	2	+350.0%
Increased positions	5	5	–
Reduced positions	6	3	+100.0%

13F shares	Current	Prev Q	Change
Total value	11.79 bn	20.18 bn	-41.6%
Total shares	27.96 mm	32.85 mm	-14.9%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Investissement Quebec	9.12 mm	$8.21 mm	0.0%
Soleus Capital Master Fund	5.19 mm	$7.47 mm	0.0%
Soleus Capital Management	4.80 mm	$5.95 bn	0.0%
Hirschman Orin	4.15 mm	$3.82 mm	0.0%
AIGH Capital Management	3.73 mm	$4.61 bn	0.0%
NA.R National Bank of Canada	186.82 k	$231.65 mm	+29.4%
Advisor	145.25 k	$181.56 mm	+0.3%
Cyndeo Wealth Partners	131.31 k	$162.83 mm	+26.1%
Federation des caisses Desjardins du Quebec	85.49 k	$105.17 mm	-8.1%
SF Stifel Financial	80.85 k	$100.25 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Nantahala Capital Management	0.00	-2.68 mm	EXIT
MS Morgan Stanley	0.00	-2.25 mm	EXIT
Harbour Investments	73.12 k	+73.12 k	NEW
Hamilton Capital	0.00	-44.07 k	EXIT
NA.R National Bank of Canada	186.82 k	+42.44 k	+29.4%
GWM Advisors	42.46 k	+34.21 k	+414.7%
Creative Financial Designs	0.00	-28.34 k	EXIT
Cyndeo Wealth Partners	131.31 k	+27.19 k	+26.1%
Beacon Pointe Advisors	0.00	-26.53 k	EXIT
UBS UBS	2.69 k	-14.85 k	-84.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Theratechnologies Q4 2024 GAAP EPS $(0.16) May Not Be Comparable To $0.05 Estimate, Sales $25.00M Beat $22.69M Estimate

Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $0.05 by 420 percent. This is a 100 percent decrease over losses of $(0.08) per share from the

Earnings Scheduled For February 26, 2025

Reported Earlier, Theratechnologies Resumes Distribution Of EGRIFTA SV As FDA Clears Two Newly Manufactured Batches

Review of the Company's Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025.EGRIFTA SV® is distributed in the United States only.

Reported Earlier, Theratechnologies Alerts Patients to EGRIFTA SV Supply Shortage Amid Manufacturing Shutdown

Theratechnologies Has Submitted A Prior Approval Supplement To The U.S. FDA Describing The Changes Made To The Manufacturing Environment Of The Facility Where EGRIFTA SV Is Produced

Press releases

From Benzinga Pro

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding latest guidance of $17-19 million Achieved record quarterly revenue of $25 million and annual revenue of

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a specialty biopharmaceutical company focused on the commercialization of innovative

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a specialty biopharmaceutical company focused on the commercialization of innovative

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.